Formulating Questions for Clinicians to Understand a CML Diagnosis

Commentary
Video

Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.

In a discussion with CancerNetwork® at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, Claire Saxton, MBA, highlighted different types of questions patients with chronic myeloid leukemia (CML) can ask their providers to receive the best possible care.

Saxton, the executive vice president of Insights and Impact at Cancer Support Community, discussed how patients should ask about prior experience their providers have with managing CML, which can help ensure that they are receiving care from experts with knowledge on all the latest advances in the field. Ultimately, she recommended that those with CML should ask their providers any questions that may help them further understand what types of therapy are most suitable for them.

Transcript:

It’s overwhelming when you’re first diagnosed with CML. People get the strangest explanations of what CML is, including, "It’s a good cancer." No cancer is a good cancer. It’s a cancer that’s very treatable, but you’re going to have to be treated for the rest of your life. One question to ask [providers] is, "How many [patients with] CML have you treated?" It’s best to get with a provider who has an understanding of the most recent advances in CML treatment.

Another thing to ask your provider is, "Is there anything particular about my CML that would make one treatment a better option for me than another, and furthermore, is there a clinical trial that’s right for me?" In CML right now, there are some exciting trials to be looking at for your treatment. Those are all big things to be asking at a time when you’re very overwhelmed.

Also, ask every question that comes to mind. There are no stupid questions. If you don’t understand the answer, ask it again. If you’re a visual person, ask [for providers] to write it down or draw it out. Because the important thing is [that CML] is a marathon to get through. The important thing is for you to slowly understand everything well enough so that you can be an active part of your treatment team and help decide what treatments are best for you.

Recent Videos
ctDNA reductions or clearance also appeared to correlate with a decrease in disease burden during the pre-boost phase of radiotherapy.
Investigators evaluated ctDNA as a potentially noninvasive method to predict response to radiotherapy among those with gynecologic malignancies.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Raymond B. Mailhot, MD, MPH, discussed how radiation therapy can impact education and survivorship for pediatric survivors of brain tumors.
Significant results from a retrospective analysis of brain tumor survivor academic performance after radiotherapy emerged despite small sampling size.
Findings may help providers and patients with head and neck cancer consider whether to proceed with radiotherapy modalities, such as proton therapy or IMRT.
Raymond B. Mailhot, MD, MPH, discussed methods for comparing academic performances of patients following radiation therapy with healthy control groups.
Study results appear to affirm anecdotal information from patients with head and neck cancer related to taste changes during and after radiotherapy.
Noah S. Kalman, MD, MBA, describes the rationale for using a test to measure granular details of taste change in patients undergoing radiotherapy for HNC.
Related Content